Dexamfetamine–associated bruxism management
Jaw clenching/bruxism temporally associated with dexamfetamine use is managed first by addressing the precipitating medication and then by symptom-directed dental and pharmacologic therapy when needed. Conservative measures (behavioral strategies and an occlusal stabilization appliance to protect the dentition) are recommended while evidence for drug therapies is limited. [1], [2]
Medication-related interventions
Medication adjustment is a first-line strategy because many cases of drug-induced bruxism improve after dose reduction, discontinuation, or switching the offending agent. [2]
Practical medication strategies include:
- Dexamfetamine dose reduction to the lowest effective dose for ADHD symptom control. [2]
- Switching stimulant formulation or stimulant agent (for example, changing to a different amphetamine or to methylphenidate) when bruxism persists. [2]
- Switching to a nonstimulant ADHD medication when bruxism remains clinically significant despite stimulant adjustment. [2]
- Addressing contributing sleep factors such as caffeine use and stress, since these are associated with bruxism activity. American Academy of Sleep Medicine (Sleep Education)—Bruxism
Dental protection and mechanical therapies
An occlusal stabilization splint (stabilization mouthguard) is recommended for protecting teeth and reducing masticatory muscle load during symptomatic periods. [1], American Academy of Sleep Medicine (Sleep Education)—Bruxism
Evidence limitations relevant to splints:
- A systematic review found insufficient evidence to determine whether occlusal splints provide benefit over no treatment or other therapies for bruxism outcomes. [3]
Behavioral and self-management interventions
Behavioral interventions are recommended to reduce daytime clenching and to reduce nocturnal bruxism contributors.
Common evidence-supported components include:
- Stress reduction and relaxation strategies when psychosocial stress is a trigger. [1]
- Lifestyle modification including limiting caffeine and avoiding alcohol before sleep when these factors exacerbate bruxism. American Academy of Sleep Medicine (Sleep Education)—Bruxism
Pharmacologic interventions for bruxism symptoms
Systemic pharmacotherapy is generally reserved for refractory bruxism with pain or functional impairment because placebo-controlled evidence is limited and studies are small.
Benzodiazepines (example: clonazepam)
Benzodiazepines are used in practice for nocturnal bruxism, supported by older placebo-controlled trials showing reductions in rhythmic masticatory muscle activity in selected populations. [4], [5]
Alpha-2 agonists and beta-blockers (example: clonidine, propranolol)
Sympatholytic agents have been studied for sleep bruxism with small trials and mixed results. [4]
Dopaminergic therapy (example: levodopa) and dopamine agonists (example: bromocriptine)
Dopaminergic agents have been evaluated in placebo-controlled studies with limited and inconsistent evidence. [4]
Botulinum toxin for refractory cases
Botulinum toxin injections into masticatory muscles are considered for severe, refractory bruxism or prominent masticatory myofascial pain when conservative therapy fails. [6]
Evidence base:
- Systematic reviews and clinical summaries support symptomatic improvement in selected studies, but results vary across study designs and bruxism phenotypes. [7]
Treatment initiation thresholds and escalation triggers
Escalation beyond medication adjustment and dental protection is appropriate when at least one is present:
- Persistent pain in jaw muscles or temporomandibular joints despite conservative measures. [1]
- Functional impact such as impaired mastication, significant tooth wear progression, or sleep disruption. [1]
- Refractory symptoms after an adequate trial of occlusal stabilization plus medication adjustment. [6]
Common pitfalls to avoid
- Attributing bruxism solely to occlusal factors without addressing medication and sleep contributors, which can lead to ineffective treatment. [1]
- Relying on occlusal splints as curative therapy despite evidence that benefit over control therapies is uncertain. [3]
Therapeutic goals
Therapy is aimed at:
- Preventing dental damage through tooth protection during active bruxism. American Academy of Sleep Medicine (Sleep Education)—Bruxism
- Reducing masticatory muscle pain and dysfunction when present. [1]
- Minimizing bruxism triggers, particularly stimulant-associated effects and sleep-related contributors. [2], American Academy of Sleep Medicine (Sleep Education)—Bruxism